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Abstract
The term mucositis is coined to describe the adverse
effects of radiation and chemotherapy treatments.
Mucositis is one of the most common adverse
reactions encountered in radiation therapy for head
and neck cancers, as well as in chemotherapy, in
particular with drugs affecting DNA synthesis (S-
phase–specific agents such as fluorouracil, metho-
trexate, and cytarabine). Mucositis may limit the
patient’s ability to tolerate chemotherapy or radiation
therapy, and nutritional status is compromised. It may
drastically affect cancer treatment as well as the
patient’s quality of life. The incidence and severity of
mucositis will vary from patient to patient. It will also
vary from treatment to treatment. It is estimated that
there is 40% incidence of mucositis in patients treated
with standard chemotherapy and this will not only
increase with the number of treatment cycles but also
with previous episodes. Similarly, patients who under-
go bone marrow transplantation and who receive high
doses of chemotherapy have a 76% chance of getting
mucositis. Patients receiving radiation, in particular to
head and neck cancers, have a 30% to 60% chance.
The exact pathophysiology of development is not
known, but it is thought to be divided into direct and
indirect mucositis. Chemotherapy and/or radiation
therapy will interfere with the normal turnover of
epithelial, cells leading to mucosal injury; subse-
quently, it can also occur due to indirect invasion of
Gram-negative bacteria and fungal species because
most of the cancer drugs will cause changes in blood
counts. With the advancement in cytology, a more
precise mechanism has been established. With this
understanding, we can select and target particular
mediators responsible for the mucositis. Risk factors
such as age, nutritional status, type of malignancy,
and oral care during treatment will play important roles
in the development of mucositis. Many treatment
options are available to prevent and treat this con-
dition, but none of them can completely prevent or
treat mucositis. More and more pathological methods
are being developed to understand this condition so
that better therapeutic regimens can be selected.
Emphasis also should be made in assessing the
patient’s psychologic condition, particular depressive
disorders. This is important because treatment with
antidepressants will not only contribute in lifting
depression but also reduces pain somatization.
Although mucositis is rarely life-threatening, it will
interfere with treatment of cancer to a great extent.
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Introduction
Chemotherapy and radiation therapy are the most widely used
interventions for the treatment of cancer. Although these treat-
ments are employed to improve the patient’s quality of life, they
are associated with several side effects. Severe adverse
reactions due to these therapies result in patient morbidity
and mortality. In addition, they also contribute to economic
ramifications of the affected patient. Annually, there are ap-
proximately 400,000 cases of treatment-induced damage to
the oral cavity [1]. Oral complications that arise with chemo-
therapy and/or radiation therapy include mucositis (stomatitis);
xerostomia (dry mouth); bacterial, fungal, or viral infection
(particularly in neutropenic patients); dental caries; loss of
taste; and osteoradionecrosis [2]. Oral mucositis also repre-
sents a major nonhematologic complication of cytotoxic che-
motherapy and radiotherapy associated with significant
morbidity, pain, odynodysphagia, dyseugia, and subsequent
dehydration and malnutrition [3]. Severe oral toxicities can also
compromise the delivery of optimal cancer therapy protocols.
For example, dose reduction or treatment schedule modifica-
tions may be necessary to allow for resolution of oral lesions. In
cases of severe oral morbidity, the patient may no longer be
able to continue cancer therapy; treatment is then usually
discontinued. These disruptions in dosing due to oral compli-
cations can directly affect patient survivorship.
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The term oral mucositis emerged in the late 1980s to
describe the adverse effects of chemotherapy-induced and
radiation therapy–induced inflammation of the oral mucosa.
Symptoms of mucositis vary from pain and discomfort to an
inability to tolerate food or fluids. Mucositis may also limit the
patient’s inability to tolerate either chemotherapy or radiation
therapy, resulting in dose-limiting toxicity and hence drasti-
cally affecting cancer treatment and outcome.
Epidemiology
Incidence as well as severity may vary from patient to
patient. The probability of developing mucositis is dependent
upon the treatment. It is estimated that about 40% of patients
treated with standard chemotherapy develop mucositis [4].
The risk of developing mucosal injury increases with the
number of chemotherapy cycles and previous episodes of
chemotherapy-induced mucositis. To our knowledge, there
should be a qualitative difference between the severity of oral
mucositis induced by radiation and that induced by chemo-
therapy. But we have no supporting literature to confirm this.
Drugs affecting DNA synthesis (S-phase–specific agents
such as fluorouracil, methotrexate, and cytarabine) exhibit
more pronounced stomatotoxic effects [5]. It is estimated
that there is an increased risk of mucositis development with
bolus and continuous infusions compared to prolonged or
repetitive administration of lower doses of cytotoxic agents
[5,6]. In patients who undergo bone marrow transplantation
and receive high-dose chemotherapy, the incidence is ap-
proximately 76%. Between 30% and 60% of patients receiv-
ing radiation therapy for cancer of the head and neck may
develop oral mucositis, and greater than 90% of patients
receiving concomitant chemotherapy and localized radiation
therapy will be affected [4,7]. The degree and duration of
mucositis in patients treated with radiation therapy are
related to radiation source, cumulative dose, dose intensity,
volume of radiated mucosa, smoking, alcohol consumption,
and oral hygiene [8,9]. Mucosal erythema occurs in the first
week in patients treated with standard 200 cGy of daily
fractionated radiotherapy programs. Patchy or confluent
mucositis peaks during the fourth to fifth weeks of treatment
with the same dose of radiation. With daily fractionated
programs of <200 cGy, the severity of mucositis is expected
to be low. However, in accelerated radiotherapy programs,
mucositis peaks within 3 weeks of the radiation therapy.
Mucositis caused by interstitial radioactive implants usually
appears in 7 to 10 days and peaks after 2 weeks [10].
A variety of patient-related factors are responsible for the
increased potential for developing mucositis after chemo-
therapy or radiation therapy. It is stated that up to 75% of the
general population has chronic periodontal disease, and it is
also hypothesized that many acute bacterial superinfections
may follow chemotherapy. Patients with improved oral hy-
giene who can abstain from smoking can definitely reduce
the incidence and severity of mucositis [11].
Pathophysiology
The exact pathophysiology of mucositis is not fully elucidat-
ed, but it is thought to have twomechanisms: direct mucositis
and indirect mucositis, caused by chemotherapy and/or
radiation therapy.
Direct Mucositis
The epithelial cells of the oral mucosa undergo rapid
turnover, usually every 7 to 14 days, which makes these
cells susceptible to the effects of cytotoxic therapy. Both
chemotherapy and radiation therapy can interfere with the
maturity and cellular growth of epithelial cells, causing
changes to normal turnover and cell death [4].
Indirect Mucositis
Oral mucositis can also be caused by the indirect invasion
of Gram-negative bacteria and fungal species. Patients are
at increased risk for oral infections when they are neutro-
pinic, and this usually happens when indirect stomatotoxicity
appears. The onset of mucositis secondary to myelosup-
pression varies, depending upon the timing of the neutrophil
nadir associated with the chemotherapy agent administered,
but typically develops anywhere from 10 to 21 days after
chemotherapy administration [12].
Based on the above consideration, new pathophysiology
concepts have emerged, and the mechanism of mucositis
involves four phases as described below [13] (Figure 1):
Phase I: Initial inflammatory/vascular phase: During this
phase, exposed cells (epithelial, endothelial, and connective
tissue cells) in the buccal mucosa release free radicals,
modified proteins, and proinflammatory cytokines, including
interleukin-1B, prostaglandins, and tumor necrosis factor
(TNF). These inflammatory mediators cause further damage
either directly or indirectly by increasing vascular permeabil-
ity, thereby enhancing cytotoxic drug uptake into the oral
mucosa [14].
Phase II: Epithelial phase: In this phase, chemotherapy
and/or radiation retards cell division in the oral mucosal
epithelium, leading to reduced epithelial turnover and re-
newal, resulting in epithelial breakdown. This results in
erythema from increased vascularity and epithelial atrophy
4 to 5 days after the initiation of chemotherapy. At this stage,
microtrauma from day-to-day activities such as speech,
swallowing, and mastication leads to ulceration.
Phase III: Ulcerative/bacteriological phase (pseudomem-
braneous): Epithelial breakdown ultimately results in the
ulcerative phase, which occurs within 1 week of therapy.
Loss of epithelia and furious exudation lead to the formation
of pseudomembranes and ulcers. In this phase, microbial
colonization of damaged mucosal surfaces by Gram-nega-
tive organisms and yeast occurs, and this may be exacer-
bated by concomitant neutropenia. Infectious complications
arising in neutropinic bone marrow transplantation recipients
are among the most challenging aspects of aggressive
myelosuppressive antineoplastic drug therapy. There are
numerous reports that demonstrate the importance of ulcer-
ative mucositis as an etiologic factor in the development of
systemic a-hemolytic streptococcal infections in the neutro-
pinic cancer patients [15].
Phase IV: Healing phase: The duration of this phase
usually lasts from 12 to 16 days, and mainly depends on
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factors such as epithelial proliferation rate, hematopoietic
recovery, reestablishment of the local microbial flora, and
absence of factors interfering with wound healing viz. infec-
tion and mechanical irritation [13].
Risk Factors for the Development of Mucosal Injury
Some of the major risk factors include age, nutritional status,
type of malignancy, oral care during treatment, and neutro-
phil count before treatment. In general, younger patients are
more prone to mucositis because of rapid epithelial mitotic
rate, or the presence of more epidermal growth factor
receptors [16]. Similarly, physiological decline in renal func-
tion with aging may also contribute to the development of
mucositis in the elderly [17]. There are reports stating that
poor oral hygiene can also contribute to the development of
mucositis following chemotherapy and/or radiation therapy
[18]. The repair of ill-fitting dental prostheses, elimination of
periodontal disease, and extraction of offending teeth, com-
bined with effective oral hygiene during treatment, has
demonstrated a reduction in the incidence and severity of
mucositis [16]. In patients who are nutritionally compro-
mised, there is always a chance for poor mucosal regener-
ation, which will in turn contribute to the development of
severe mucositis [18]. Chemotherapy-induced mucositis is
more common in hematological cancers because of more
prolonged and intense myelosuppression (depending also
on the chemotherapeutic agent given) and radiation-induced
mucositis is common in head and neck cancers because of
direct irradiation on the oral cavity (depending also on the
dose and type of radiation) [16]. Polypharmacy is more
common in cancer patients because of underlying comorbid-
ities. Depressive disorders are one of the most common
psychiatric complications in cancer patients and most of the
antidepressants have anticholinergic activities, which con-
tribute to xerostomia leading to mucositis. Other drugs that
are most commonly overlooked are opiates, phenothiazines,
antihypertensives, antihistamines, sedatives, and so on [19].
The drugs that are commonly responsible for oral mucositis
are shown in Table 1. The exact incidences of different
chemotherapeutic agents are lacking. Still, adverse drug
reaction (ADR) monitoring studies have to be carried out to
understand the exact incidence of oral mucositis. Certain
chemotherapeutic agents such as methotrexate and etopo-
side may also be secreted in saliva, leading to increased risk
of direct mucositis [20]. Recent studies have hypothesized
that decreased neutrophil count is the risk factor for the
development of mucositis [18]. Drugs causing mucosal dam-
age are given in Table 1.
Assessment of Mucosal Injury
In routine clinical practice as well in the area of research,
proper assessment of oral mucosa is of paramount impor-
tance before initiating radiation therapy to the head and neck
regions, as well as chemotherapy. A variety of protocols and
grading systems have been introduced, but only a few of
them are standardized and validated. A good scoring system
is that which will consider all patient-related factors viz. the
patient’s physical and nutritional status combined with a
detailed inspection of the oral cavity. Clinical severity of
mucosal injury will vary from mild, to moderate, to severe.
Standardized criteria that are routinely used for clinical and
research purposes are described below:
World Health Organization (WHO) grading of mucositis:
This scoring system is widely used in routine clinical practice
and clinical trials for the evaluation of mucositis. It is graded
from 0 to 4. If the patient has no signs and symptoms, it is
graded as 0. If the patient has painless ulcers, edema, or
mild soreness, it is graded as 1. If there is painful erythema,
edema, or ulcers but able to eat, it is graded as 2. If there
is painful erythema, edema, or ulcers but unable eat, it is
graded as 3. If there a requirement for parenteral or enteral
support, it is graded as 4 [7].
National Cancer Institute common toxicity criteria for
grading of stomatitis [7]: This scale is also graded from 1 to 4.
Figure 1. Flow chart representing the different phases of mucositis
development with chemotherapy and/or radiation therapy.
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Painless ulcers, erythema, or mild soreness is graded as 1.
When thepatient has painful erythema, edema, and ulcer but is
able to eat, it is graded as 2. When there is inability to eat, it is
graded as 3. A patient requiring parenteral or enteral support is
graded as 4.
Radiation therapy oncology oral mucositis grading sys-
tem: This scale is divided into gross and functional. Gross is
the one which is assessed by the attending physician or a
research personal, and functional is assessed by the patient.
It is scored from 0 to 4, wherein the presence of erythema-
tous sores is scored as 1, patchy mucositis (<1/2 mucosa)
is scored as 2, fibrinous mucositis (>1/2 mucosa) is scored
as 3, and, similarly, hemorrhage and necrosis are scored
as 4 [7].
Oral assessment guide (OAG): This is a very important
tool for evaluating mucositis. Its validity and interreliability
testing have been established. When oral cavity status
changes secondary to chemotherapy and/or radiation ther-
apy are quantified through the use of reliable and valid OAG,
researchers can study the effectiveness of different oral care
protocols and can identify the individuals at risk for problems
secondary to stomatitis. It mainly consists of eight items,
which are rated from 1 to 3 [21].
Objective scoring system for site assessment: This is a
more commonly used scoring system for assessing site
involvement in oral mucositis induced by chemotherapy with
or without radiation therapy. It consists of nine items wherein
one can assess the site and size of ulcers and the severity of
erythema. It is scored from 0 to 3. Zero indicates no lesions;
if the size is less than 1 cm2, then it is scored as 1. If the size
is between 1 and 2 cm2, it is scored as 2. If it is greater than
3 cm2, it is scored as 3. Similarly, depending on the severity
of erythema, it is scored from 0 to 2. Zero indicates no
erythema, 1 indicates nonsevere erythema, and 2 indicates
severe erythema [22].
Although the grading of mucositis is necessary to docu-
ment its degree and to evaluate the effect of prevention or
intervention, most of these scoring systems can be applied
only for clinically visible mucositis. It may not correlate with
complaints of patients. However, all these scoring systems
remain subjective; a lot of intervariability is possible. Thus,
recently, new in vitro assays for quantitation of mucosal
injury have been established. Following are some of the
objective pathological parameters that define mucosal injury
induced by radiation or chemotherapy [23].
Estimation of Cell Viability in Mouthwashes
Trypan blue dye exclusion method is a method commonly
used in cytology to assess the number of living cells and
dead cells in the oral mucosa. The main principle involved
in the test is that trypan blue will stain dead or dying cells.
Viable cells are able to repel the dye and do not stain. In
general, this test is used regularly in tissue cultures to
determine the number of live cells for planting. This test
is also being used to assess cell viability in patients with
mucositis. Machteld et al. conducted a phase I study of
transforming growth for the prevention of chemotherapy-
induced mucositis wherein authors used the assessment
of cell viability as a secondary outcome measure to study
the effect of TGF-b3. Authors have concluded that there
is an increase in the total viable cells in patients treat-
ed with different standard chemotherapeutic regimens [23].
Estimation of Neutrophil Levels in Mouthwashes
One of the significant causes of morbidity with respect to
mucositis in patients treated with high-dose chemotherapeu-
tic agents is infection. It is well established that the risk of
infection increases with the severity and duration of neutro-
pinic episodes. Graham et al. [24] conducted a study on
healthy volunteers to establish the normal count of neutro-
phils in oral rinses. It was found to be 472 ± 329  103
compared to undetectable levels found in patients on che-
motherapy. In this assay, mouthwash with normal saline is
collected in centrifuge tubes containing acridine orange.
Counting of orange granular cytoplasm is done on a he-
mocytometer. This method is an important tool to moni-
tor neutrophil levels in patients who are at high risk for
mucositis [24].
Epithelial Cell Morphology and Differentiation/
Maturation
The oral mucosa will respond to physical, chemical, or
biologic agents, leading to ulcerations and inflammations.
Scrapings from these lesions may reveal cells whose cyto-
plasm is abnormally acidophilic, with enlarged nuclei and
scanty surrounding cytoplasm, or both [25]. A study con-
ducted by Wymenga et al. reveled that the number of viable
cells increases from baseline in patients receiving chemo-
therapy. In an attempt to understand the maturity of these
epithelial cells, Papanicolaou staining technique had been
performed. According to this technique, cells with orange
color are considered to be mature cells; green or blue in-
dicate immature cells; and partial orange and partial green/
blue are considered to be intermediate cells [23,24,26].
Quality of Life
Quality of life is defined as an individual’s perceptions of his/
her position in life in the context of culture and value systems
in which he/she lives in relation to his/her goals, expectations,
and concerns [27]. Over the past decade, there has been a
Table 1. Different Chemotherapeutic Agents Known to CauseMucosal Injury.
Chemotherapeutic Agents Causing Mucositis [24]
Alkylating agents
Busulfan
Cyclophosphamide, thiotepa, procarbazine
Anthracyclines
Doxorubicin, epirubicin, daunorubicin
Antimetabolites
5-FU, methotrexate, hydroxyurea
Antitumor agents
Actinomycin D, bleomycin, mitomycin
Taxanes
Paclitaxel
Vinca alkaloids
Vincristine, vinblastine
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dramatic increase in the use of quality-of-life measurements
in clinical trials. Improving the quality of patients’ lives has
become as important as extending the quantity of life. Radi-
ation-induced mucositis is a very severe complication where-
in patients’ daily living habits are compromised. Thus, the
treatment aimed to reduce the symptoms of mucositis should
also aim to improve the quality of life. To our knowledge, very
few studies have been carried out in this area.
Treatment Options Available for Oral Mucositis
Preventive Treatment
Currently, no intervention that is completely successful at
preventing oral mucositis exists [7]. Despite the availability of
many therapeutic agents that claim to prevent or reduce
severity, oral mucositis often takes a therapeutically refrac-
tory turn, necessitating the use of topical and systemic
analgesics. This following part of the paper attempts to
review different treatment options available to prevent and
treat this condition. However, evaluations of different modal-
ities are difficult because of polypharmacy, heterogeneity,
and relatively small patient populations in clinical trials. On
top of this, most of the trials that have been conducted were
based on subjective evaluation systems. There are very few
studies evaluated using pathological tests as objective
measures. Prevention measures play important roles be-
cause the incidence of mucositis with radiation therapy to the
oral cavity in head and neck cancer patients with or without
chemotherapy is well established [7] (Figure 2).
Oral Hygiene
Patients should be referred to the dentist for a compre-
hensive examination to identify and correct any potential
complication before cancer therapy is initiated. This includes
the identification of infections requiring prompt antibiotic
therapy to prevent systemic infection. Patients are encour-
aged to seek professional dental care throughout cancer
Figure 2. Flow chart of management.
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therapy, as necessary. Most importantly patients, are
instructed to brush their teeth with soft toothbrush and
fluoridated toothpaste after every meal and before bedtime
everyday, and toothbrush should be changed monthly [7].
Patients should be encouraged to take a nutritious and
balanced diet.
Cryotherapy
It has been hypothesized that cooling of oral mucosa
using ice chips will reduce the blood flow to the oral mucosa,
thus reducing the availability of chemotherapeutic agents to
the oral mucosa [28].The North Central Cancer Treatment
Group (NCCTG) conducted studies on 95 patients receiving
their first course of 5FU-based chemotherapy versus non-
therapy. The patients who received oral cryotherapy had
approximately 50% reduction in stomatitis [29]. But to our
knowledge, there are no confirmatory studies.
Allopurinol
Oxypurinol, which is the metabolite of allopurinol, inhibits
an enzyme involved in pyrimidine synthesis, leading to
intracellular accumulation of orotic acid. This compound, in
turn, inhibits the activation of 5FU to fluorouracil monophos-
phate, thus diminishing 5FU toxicity. Although initial pilot
studies conducted by Bleyer [30] showed beneficial effects
of allopurinol mouthwashes, studies conducted by the
NCCTG showed an increase in 5FU-induced mucositis for
patients receiving the allopurinol mouthwash.
Propantheline
Propantheline is an anticholinergic agent that is known to
produce dry mouth and xerostomia. Chemotherapeutic
agent etiposide is known to be excreted in the saliva; it
was hypothesized that propantheline may reduce dose-
limiting toxicity in patients receiving etiposide. Randomized
trials have shown a reduction in incidence and severity of
mucositis [31].
Pilocarpine
Pilocarpine is a cholinergic agonist that has demonstrated
efficacy in relieving symptoms of radiation-induced mucosi-
tis. Johnson et al., who conducted preliminary studies,
suggest that administration of pilocarpine will preserve sal-
ivary gland function when used for patients receiving radio-
therapy. Still double-blind randomized studies are required
to conclude its efficacy in preventing mucositis [32].
Cytokines
Oral mucosal defense mechanism is enhanced by the
local accumulation of activated neutrophils subsequent to
systemic administration of granulocyte colony-stimulating
factor (G-CSF) and granulocyte–macrophage colony-stim-
ulating factor (GM-CSF). In addition to this, topical adminis-
tration of G-CSF and GM-CSF has promising effects on the
oral mucosa [33].
GM-CSF mouthwashes have been shown to cause
marked alleviation of existing oral mucositis in several stud-
ies without detectable systemic accumulation of GM-CSF or
effects upon systemic neutrophil counts [34]. Reduction in
chemotherapy-induced mucositis was observed coinciden-
tally with amelioration of neutropenia after chemotherapy. It
was first reported by Antman et al. that there is a 75%
decrease in the incidence of oral mucositis when G-CSF
was included in the M-VAC (methotrexate, vinblastine, dos-
orubicin, and cisplatin) chemotherapy regimen. A similar
effect was observed when GM-CSF was given with doxoru-
bicin, ifosfamide, and dacarbazine chemotherapy [35]. But
all studies that have been conducted were nonrandomized
studies. Kwan-Hawa et al. have conducted a first random-
ized, prospective controlled study to evaluate the effect of
GM-CSF versus no treatment on the reduction of salivary-
induced oral mucositis and duration of chemotherapy-in-
duced oral mucositis. In this study, 20 patients with (PFL)
cisplatin, fluorouracil, and leucovorin chemotherapy regimen
(20 mg/mm per day cisplatin, 800 mg/mm per day 5FU, 90
mg/mm per day leucovorin) was selected because it is
effective for the treatment of head and neck cancers and
often induces oral mucositis. The results of this study indi-
cated that GM-CSF has reduced the severity and duration of
mucosal injury [34,36]. The effects of these agents also vary
with the route and time of administration. But it still remains
uncertain whether GM-CSF or G-CSF administered topically
or intravenously has any beneficial effects [37]. Machteld
et al. have conducted a phase I trial on transforming growth
factor-b3 (TGF-b3) mouthwashes for the prevention of che-
mo-induced mucositis. Evaluations of both subjective and
objective parameters were performed on 11 patients. The
primary aim was to evaluate the safety and tolerability of the
mouthwash and, secondary, was to evaluate the efficacy.
Out of 11 patients, three of them had increases in WHO
scores (>grade 0 and maximum grade 3). No unexpected
adverse events were observed at the dose of 100 mg/ml per
day. Still controlled clinical trials have to be performed to
conclude the efficacy of the preparation [23].
Amifostine
Amifostine in a local application (250 mg) form has shown
mixed response in the preventive treatment of radiochemo-
therapy-induced mucositis. A study conducted by Vacha
et al. has shown significant radioprotective effects on sali-
vary glands and a potential effect on oral mucosa by amifos-
tine in postoperative radiotherapy combined with carboplatin.
But to conclude, further randomized trials should be con-
ducted on the beneficial effects of amifostine in patients
receiving radiation and chemotherapy [38].
Dinoprostone
Prostaglandin E2 (PGE2), which is a naturally occurring
cytoprotective agent, has been reported to be beneficial in
healing gastric ulcers and chronic leg ulcers. Studies that
have been conducted have shown promising results as
preventive treatment to chemotherapy-induced and radiation
therapy–induced mucositis [7]. A randomized double-blind
trial comparing topically applied PGE2 versus placebo in 60
patients undergoing bone marrow transplantation for acute
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leukemia has not shown promising results in reducing the
severity and incidence of mucosal injury [39].
Antimicrobial/Antifungal/Antiviral Agents
The oral mucosa of cancer patients is colonized by a
variety of potentially pathogenic microorganisms such as
Gram-positive and Gram-negative opportunistic bacteria
and fungi. Antibiotic lozenges containing polymyxin E and
tobramycin (and amphotericin B) have successfully eliminat-
ed microbial flora and prevented severe forms of oral mu-
cositis, compared to controls in patients with radiation
treatment in head and neck cancers. Although fungi are
not primarily involved in the development of oral mucositis,
they account for the most frequent infections of the dam-
aged mucosa in the immunosuppressed patients. The fre-
quently used polyene antifungals such as nystatin have been
evaluated in clinical trials and failed to show impressive
results. Viruses, particularly herpes simplex virus type I
(HSV) and varicella zoster virus (VZV), represent the most
common pathogens aggravating oral mucositis in the course
of antineoplastic therapy. For seropositive and myelosup-
pressed patients, topical and systemic acyclovir treatment is
effective in the management of oral herpetic infections [40].
Chamomile
The chamomile plant (Matricaria chamomilla) has been
used for medicinal purposes for centuries. This plant con-
tains many active constituents including chamazulene,
a-bisabolol, bisabolol oxides, spiroethers, and flavanoids.
Data pertaining to this suggest that these compounds have
anti-inflammatory, antibacterial, and antifungal properties.
Initial preliminary uncontrolled studies suggested that this
compound has shown good results in reducing the sever-
ity and duration of mucositis in a smaller group of popula-
tion [41]. However, later phase III trials have failed to
conclude that the chamomile given in mouthwash formula-
tions is effective in patients with chemotherapy-induced
mucositis [42].
Traumeel S (Homeopathic Medication)
Traumeel S, a homeopathic medication in the form of
mouth rinse, has been tried on patients undergoing alloge-
neic or autologous stem cell transplantation. This study
indicated that Traumeel S may reduce significantly the
severity and duration of chemotherapy-induced stomatitis;
however, a limited number of patients in the trial may not be
sufficient to prove its efficacy [43].
Glutamine
Suspension of glutamine has been tried in different trials
with inconclusive results. Huang et al. have conducted a pilot
study in radiation-induced oral mucositis, and authors con-
cluded that glutamine may significantly reduce the duration
and severity of oral mucositis. However, the number of
patients who received the active drug was only eight [44].
In another study conducted by Jebb et al., which evaluated
5FU-induced and folinic acid– induced mucositis in 28
patients, it was concluded that there is no effect of oral
glutamine supplementation [45].
Keratinocyte Growth Factor-2 (KGF-2)
KGF-2 selectively induces epithelial cell proliferation,
differentiation, and migration. KGF-2 has no in vitro and
in vivo proliferative effects on human epithelial– like tumors.
This failure to stimulate tumor cell growth highlights the
ability of this drug to specifically target normal epithelial
tissue [46]. In a study wherein KGF-2 was given as an
intravenous formulation, it was well tolerated by patients
and it reduced the severity of mucosal injury in patients
receiving intravenous bolus 5-FU [47].
Treatment Options of Established Mucositis
Patient education is very important in managing chemother-
apy-induced and/or radiation-induced mucositis. Patients
should be motivated to follow guidelines indicated below to
reduce the discomfort caused by mucositis:
 Patients are encouraged to sit upright at a 90j angle and
lean their head slightly forward.
 Eat slowly. Food should be cut in to small pieces and
chewed completely.
 Eat small frequent meals instead of heavy meals.
 Food taken should be warm, or at room temperature. Hot
food and drinks should be avoided. Similarly, crunchy
foods such as potato chips and nuts should also be
avoided.
 Soft food is always encouraged. Finely chopped cooked
meat, fruits, and vegetables should be taken. Patients
can also try commercial baby foods, which are nutritious,
convenient, and very easy to swallow. Milk shakes that
have very high proteins can also be tried.
 Usage of straw will not only make drinking easy but will
also avoid direct contact with the affected portion.
 Do not talk while food is in the mouth.
 Acidic foods such as tomatoes, grapes, apple fruits or
juices, alcohol and tobacco, and spicy foods should be
avoided.
 In order to relieve discomfort of dry mouth, patients are
asked to rinse mouth with water before and after every
meal [48].
Oral Care
Routine mouth care should be performed every 4 days.
Patient should be counseled to rinse mouth thoroughly after
every meal so that the food particles do not remain in the
mouth. The routine oral care of patients includes removal of
dentures, debridement of necrotic tissues, and oral rinse with
saline regularly. Antibiotic rinses such as chlorohexidine may
also be used; however, their efficacy remains unproven
according to the double-blind placebo-controlled study con-
ducted by Worthington et al. [48].
Topical Coating Agents
Sucralfate, magnesium hydroxide, and hydroxypropyl
cellulose are some of the film-forming or coating agents
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which may be beneficial in treating established mucositis
[49]. Sucralfate is a basic albumin salt of sucrose octasulfate
that has been approved by the US FDA for its usage in
patients with active duodenal ulcers. A preliminary random-
ized trial showed good results in reducing the severity of
mucositis in a patient population. But later, a phase III trial in
131 patients did not support the prestudy hypothesis stating
that sucralfate is beneficial in chemotherapy-induced muco-
sitis [50]. Hydroxypropyl cellulose (MGI 209), which is a
bioadhesive, may serve as a protective barrier over mucosal
ulceration, allowing pain relief and improved healing. In this
pilot study, investigators concluded that MGI 209 could
relieve oral ulcer discomfort for at least 3 hours even with
exposure to an acidic, irritating beverage [51].
Topical Anesthetics
Local anesthetics such as lidocaine, cocaine, and capsa-
icin have shown mixed results [7].
Conclusion
Oral mucositis is an extremely serious and challenging
complication of both radiation and chemotherapy in cancer
patients. Because the treatment of mucositis is limited,
prophylaxis is emphasized. Patient education with regard
to oral hygiene is stressed. Pretreatment should be aimed to
reduce systemic infection, patient’s nutritional status should
not be compromised, and, most importantly, patient’s quality
of life should not be affected. Assessment of oral pathology
is essential to minimize acute and chronic oral and systemic
sequelae of antineoplastic and radiation therapy. A number
of agents have been evaluated in clinical trials, but currently
none of them has succeeded in reaching clinical practice.
The probable reasons behind this is that most of the studies
used scoring systems that were not validated and whose
interreliability was not established; all these scoring systems
are absolutely subjective. Because now in vitro pathological
methods have been established, usage of these methods
has to be encouraged to reduce the bias of subjective
methodology. Some of the parameters to be evaluated
include the release of free radicals, modified proteins, and
proinflammatory cytokines including interleukin-1B, prosta-
glandins, and TNF by epithelial, endothelial, and connective
tissue cells. These mediators cause further damage either
directly or indirectly by increasing vascular permeability,
enhancing the cytotoxic drug in the oral mucosa. Intervention
with new antioxidants may be helpful in preventing mucosal
damage and improving quality of life. Emphasis also should
be made in assessing the patient’s psychologic condition,
in particular depressive disorders. This is important because
treatments with antidepressants will not only contribute to
lifting depression but also to reducing pain somatization.
Although mucositis is rarely life-threatening, it will interfere,
to a great extent, with the outcome of cancer treatment.
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